Influence of Cirrhosis on <sup>68</sup>Ga-FAPI PET/CT in Intrahepatic Tumors.

Peng, Dengsai; Cao, Jianpeng; Guo, Chunmei; He, Jing; Yang, Liping; Zhang, Jinping; Yang, Jian; Feng, Yue et al. · Radiology · 2023

retrospective_cohort · Level III

Where this comes from

Abstract

Background Gallium 68 (<sup>68</sup>Ga)-labeled fibroblast activation protein inhibitor (FAPI) is of great diagnostic value for intrahepatic tumors. However, cirrhosis may lead to increased <sup>68</sup>Ga-FAPI uptake in background liver, affecting the diagnostic ability of <sup>68</sup>Ga-FAPI. Purpose To assess the effect of cirrhosis on liver parenchyma and intrahepatic tumor uptake of <sup>68</sup>Ga-FAPI and to compare the ability of <sup>68</sup>Ga-FAPI and fluorine 18 (<sup>18</sup>F)-labeled fluorodeoxyglucose (FDG) PET/CT to depict intrahepatic tumors in patients with cirrhosis. Materials and Methods In this secondary analysis of a prospective trial, patients who underwent both <sup>68</sup>Ga-FAPI and <sup>18</sup>F-FDG PET/CT and those who underwent only <sup>68</sup>Ga-FAPI PET/CT between August 2020 and May 2022 were considered for inclusion in the cirrhotic or noncirrhotic group, respectively. Patients with cirrhosis were chosen via a comprehensive assessment of imaging and clinical data, and patients without cirrhosis were randomly selected. <sup>68</sup>Ga-FAPI and <sup>18</sup>F-FDG PET/CT data were measured by two radiologists. Between-groups and within-group data were tested with the Mann-Whitney <i>U</i> test and the Wilcoxon signed-rank test, respectively. Results A total of 39 patients with cirrhosis (median age, 58 years [IQR, 50-68]; 29 male; 24 intrahepatic tumors) and 48 patients without cirrhosis (median age, 59 years [IQR, 51-67]; 30 male; 23 intrahepatic tumors) were evaluated. In patients without intrahepatic tumors, the liver <sup>68</sup>Ga-FAPI average standardized uptake value (SUV<sub>avg</sub>) was higher in the cirrhotic group than in the noncirrhotic group (median SUV<sub>avg</sub>, 1.42 [IQR, 0.55-2.85] vs 0.45 [IQR, 0.41-0.72]; <i>P</i> = .002). However, no difference was observed in the diagnosis of intrahepatic tumor sensitivity (98% vs 93%, respectively). When compared with <sup>18</sup>F-FDG, the sensitivity of <sup>68</sup>Ga-FAPI PET/CT in the detection of intrahepatic tumors in patients with cirrhosis (41% vs 98%, respectively) and maximum standardized uptake value of tumors (median SUV<sub>max</sub>, 2.60 [IQR, 2.14-4.49] vs 6.68 [IQR, 4.65-10.08]; <i>P</i> < .001) were higher. Conclusion The sensitivity of <sup>68</sup>Ga-FAPI in the diagnosis of intrahepatic tumors was not affected by cirrhosis, and diagnostic accuracy of <sup>68</sup>Ga-FAPI was higher than that of <sup>18</sup>F-FDG in patients with cirrhosis. © RSNA, 2023 <i>Supplemental material is available for this article.</i>

Medical subject headings